Sun Pharmaceutical Industries
Trial Pipeline
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
NCT07144345
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT03898479
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
NCT06733402
A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
NCT06305637
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
NCT06063473
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
NCT04883593
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
NCT04883736
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
NCT04797793
A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
NCT03257943
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
NCT02932891
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
NCT02933502
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
NCT02933528
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
NCT02601469
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
NCT02618759
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
NCT01513863
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
NCT01206660
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
NCT00752973
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice
NCT00244439
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 6 |
| Phase 3 | 6 |
Therapeutic Areas
What the Pipeline for Sun Pharmaceutical Industries Shows
According to the ClinicalTrials.gov registry, Sun Pharmaceutical Industries is linked to 20 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 5% of the sponsor's indexed portfolio — and 16 are already marked complete, representing roughly 80% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Sun Pharmaceutical Industries reports 6 late-stage studies (Phase 3 and Phase 4 combined) and 14 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Sun Pharmaceutical Industries is Acne Vulgaris with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.